Browse
Submit Data
Databases
API
Help

Dataset Information

10 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Reversal Agents: What We Have and What We Can Expect.

ABSTRACT: Clinical trials in patients with atrial fibrillation have demonstrated that non-vitamin K antagonist oral anticoagulants [novel oral anticoagulants (NOACs)] are markedly safer than warfarin with respect to serious bleeding-especially intracranial hemorrhage, the most feared and devastating complication of anticoagulant therapy. Registries and large retrospective database studies have confirmed these findings. Additionally, patients who do experience bleeding while taking NOACs have similar or better outcomes than do patients on warfarin. However, despite these data, many physicians and patients have been reluctant to embrace NOAC use due to their perception that they are not able to effectively manage patients who present with bleeding, particularly without a specific reversal agent or antidote on-hand. With the approval of the first NOAC-specific reversal agent and with others in late-stage clinical development, it is helpful to review how these agents may fit in the framework of managing NOAC-related bleeding.

SUBMITTER: Ruff CT

PROVIDER: S-EPMC7252789 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Reversal Agents: What We Have and What We Can Expect.

Ruff Christian T CT

The Journal of innovations in cardiac rhythm management 20180415 4

Clinical trials in patients with atrial fibrillation have demonstrated that non-vitamin K antagonist oral anticoagulants [novel oral anticoagulants (NOACs)] are markedly safer than warfarin with respect to serious bleeding-especially intracranial hemorrhage, the most feared and devastating complication of anticoagulant therapy. Registries and large retrospective database studies have confirmed these findings. Additionally, patients who do experience bleeding while taking NOACs have similar or be ...[more]

PMID: 32477806

Similar Datasets

Reversal Agents in the Era of NOACs.

Project description:The incidence and prevalence of atrial fibrillation (AF) is expected to more than double between 2010 and 2030. Accordingly, the use of non-vitamin K oral anticoagulant (NOAC) agents for thromboembolic stroke prevention is anticipated to increase. The development of effective and safe antidotes is needed to address the unmet need for rapid anticoagulation reversal. The immediate role for these novel antidotes is for reversal of NOAC activity in life threatening bleeding and urgent surgical intervention. In addition, reversal agents may play an important role in simplifying bridging protocols in the peri-procedural period for catheter ablation of AF and elective surgery. Currently, novel reversal agents are either decoy drug receptors or small molecule non-specific anticoagulant activity inhibitors. These agents are at various stages of FDA investigation and approval, with emerging prospective data for safety and efficacy. The purpose of this review is to outline the currently developed NOAC molecular antagonists, their potential clinical roles and future directions.

| S-EPMC5821629 | biostudies-literature

Space and rank: infants expect agents in higher position to be socially dominant.

Project description:Social hierarchies exist throughout the animal kingdom, including among humans. Our daily interactions inevitably reflect social dominance relationships between individuals. How do we mentally represent such concepts? Studies show that social dominance is represented as vertical space (i.e. high = dominant) by adults and preschool children, suggesting a space-dominance representational link in social cognition. However, little is known about its early development. Here, we present experimental evidence that 12- to 16-month-old infants expect agents presented in a higher spatial position to be more socially dominant than agents in a lower spatial position. After infants repeatedly watched the higher and lower agents being presented simultaneously, they looked longer at the screen when the lower agent subsequently outcompeted the higher agent in securing a reward object, suggesting that this outcome violated their higher-is-dominant expectation. We first manipulated agents' positions by presenting them on a podium (experiment 1). Then we presented the agents on a double-decker stand to make their spatial positions directly above or below each other (experiment 2), and we replicated the results (experiment 3). This research demonstrates that infants expect spatially higher-positioned agents to be socially dominant, suggesting deep roots of the space-dominance link in ontogeny.

| S-EPMC6790788 | biostudies-literature

Preverbal infants expect agents exhibiting counterintuitive capacities to gain access to contested resources.

Project description:Claims to supernatural power have been used as a basis for authority in a wide range of societies, but little is known about developmental origins of the link between supernatural power and worldly authority. Here, we show that 12- to 16-month-old infants expect agents exhibiting counterintuitive capacities to win out in a two-way standoff over a contested resource. Infants watched two agents gain a reward using either physically intuitive or physically counterintuitive methods, the latter involving simple forms of levitation or teleportation. Infants looked longer, indicating surprise, when the physically intuitive agent subsequently outcompeted a physically counterintuitive agent in securing a reward. Control experiments indicated that infants' expectations were not simply motived by the efficiency of agents in pursuing their goals, but specifically the deployment of counterintuitive capacities. This suggests that the link between supernatural power and worldly authority has early origins in development.

| S-EPMC8149634 | biostudies-literature

Novel Latency Reversal Agents for HIV-1 Cure.

Project description:Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate HIV-1 in infected individuals. This review describes current pharmacologic approaches to reactivate the latent reservoir so that infected cells can be recognized and targeted, with the ultimate goal of achieving an HIV-1 cure.

| S-EPMC5892446 | biostudies-literature

Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.

Project description:Background: Over the last ten years, a new class of drugs, known as the direct-acting oral anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the older generation anticoagulants, DOACs require specific reversal agents in cases of life-threatening bleeding or the need for high-risk surgery. Methods: Published literature was searched, and information extracted to provide an update on DOACS and their reversal agents. Results: The DOACs include the direct thrombin inhibitor-dabigatran, and the factor Xa inhibitors-rivaroxaban, apixaban, edoxaban, and betrixaban. These DOACs all have a rapid onset of action and each has a predictable therapeutic response requiring no monitoring, unlike the older anticoagulants, such as warfarin. Two reversal agents have been approved within the last five years: idarucizumab for the reversal of dabigatran, and andexanet alfa for the reversal of rivaroxaban and apixaban. Additionally, ciraparantag, a potential "universal" reversal agent, is currently under clinical development. Conclusions: A new generation of anticoagulants, the DOACs, and their reversal agents, are gaining prominence in clinical practice, having demonstrated superior efficacy and safety profiles. They are poised to replace traditional anticoagulants including warfarin.

| S-EPMC6963825 | biostudies-literature

Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.

Project description:Oral Factor Xa (FXa) inhibitors, a growing class of direct-acting anticoagulants, are frequently used to prevent stroke and systemic embolism in patients with atrial fibrillation and to prevent and treat venous thromboembolism. These drugs reduce the risk of clotting at the expense of increasing the risk of bleeding, and currently they have no specific reversal agent. However, andexanet alfa, a recombinant modified FXa decoy molecule, is in a late-phase clinical trial in bleeding patients, and ciraparantag, a small molecule that appears to reverse many anticoagulants including the FXa inhibitors, is in development. This review summarizes the published data to date on both drugs, which have the potential to change the management approach to patients with FXa inhibitor-associated major hemorrhage.

| S-EPMC5568764 | biostudies-literature

Preclinical and clinical data for factor Xa and "universal" reversal agents.

| S-EPMC5568758 | biostudies-literature

Availability of Specific Direct Oral Anticoagulant Reversal Agents in US Hospitals.

Project description: Not available

| S-EPMC8122227 | biostudies-literature

Humans expect generosity.

Project description:Mechanisms supporting human ultra-cooperativeness are very much subject to debate. One psychological feature likely to be relevant is the formation of expectations, particularly about receiving cooperative or generous behavior from others. Without such expectations, social life will be seriously impeded and, in turn, expectations leading to satisfactory interactions can become norms and institutionalize cooperation. In this paper, we assess people's expectations of generosity in a series of controlled experiments using the dictator game. Despite differences in respective roles, involvement in the game, degree of social distance or variation of stakes, the results are conclusive: subjects seldom predict that dictators will behave selfishly (by choosing the Nash equilibrium action, namely giving nothing). The majority of subjects expect that dictators will choose the equal split. This implies that generous behavior is not only observed in the lab, but also expected by subjects. In addition, expectations are accurate, matching closely the donations observed and showing that as a society we have a good grasp of how we interact. Finally, correlation between expectations and actual behavior suggests that expectations can be an important ingredient of generous or cooperative behavior.

| S-EPMC5307963 | biostudies-literature

OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.

Project description:OSI-930, a dual c-Kit and KDR tyrosine kinase inhibitor, is reported to have undergone a Phase I dose escalation study in patients with advanced solid tumors. A series of fifteen pyridyl and phenyl analogues of OSI-930 were designed and synthesized. Extensive screening of these compounds led to the discovery that nitropyridyl and ortho-nitrophenyl analogues, VKJP1 and VKJP3, were effective in reversing ABC subfamily G member 2 (ABCG2) transporter-mediated multidrug resistance (MDR). VKJP1 and VKJP3 significantly sensitized ABCG2-expressing cells to established substrates of ABCG2 including mitoxantrone, SN-38, and doxorubicin in a concentration-dependent manner, but not to the non-ABCG2 substrate cisplatin. However, they were unable to reverse ABCB1- or ABCC1-mediated MDR indicating their selectivity for ABCG2. Western blotting analysis was performed to evaluate ABCG2 expression and it was found that neither VKJP1 nor VKJP3 significantly altered ABCG2 protein expression for up to 72 h. [(3)H]-mitoxantrone accumulation study demonstrated that VKJP1 and VKJP3 increased the intracellular accumulation of [(3)H]-mitoxantrone, a substrate of ABCG2. VKJP1 and VKJP3 also remarkably inhibited the transport of [(3)H]-methotrexate by ABCG2 membrane vesicles. Importantly, both VKJP1 and VKJP3 were efficacious in stimulating the activity of ATPase of ABCG2 and inhibited the photoaffinity labeling of this transporter by its substrate [(125)I]-iodoarylazidoprazosin. The results suggested that VKJP1 and VKJP3, specifically inhibit the function of ABCG2 through direct interaction with its substrate binding site(s). Thus VKJP1 and VKJP3 represent a new class of drugs for reducing MDR in ABCG2 over-expressing tumors.

| S-EPMC3443622 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data